Editorial: Genomic discoveries and pharmaceutical development in urologic tumors

Jialin Meng; Huan Yang; Lei Yin

doi:10.3389/fphar.2024.1508979

Editorial: Genomic discoveries and pharmaceutical development in urologic tumors

Front Pharmacol. 2024 Dec 9:15:1508979. doi: 10.3389/fphar.2024.1508979. eCollection 2024.

Authors

Jialin Meng^{1

2

3}, Huan Yang⁴, Lei Yin^{5

6}

Affiliations

¹ Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
² Institute of Urology and Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China.
³ School of Life Sciences, Anhui Medical University, Hefei, China.
⁴ Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁵ Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁶ Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

No abstract available

Keywords: cancer biomarkers; drug repurposing; drug screen; genomic sequence; urologic tumors.

Publication types

Editorial

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the National Natural Science Foundation of China (82203698). The Sailing Program of Shanghai Science and Technology Commission (22YF1425000). Anhui Province Key Project for Clinical Medical Research Translation and Advancement (202204295107020031 and 202204295107020007).